本页面由Tiger Trade Technology Pte. Ltd.提供服务

Soleno Therapeutics

37.24
-1.3900-3.60%
盘后37.400.1600+0.43%19:32 EST
成交量:169.68万
成交额:6,412.60万
市值:20.00亿
市盈率:-21.28
高:39.79
开:38.71
低:36.89
收:38.63
52周最高:90.32
52周最低:36.89
股本:5,371.00万
流通股本:4,487.09万
量比:1.60
换手率:3.78%
股息:- -
股息率:- -
每股收益(TTM):-1.7500
每股收益(LYR):-4.3770
净资产收益率:-20.66%
总资产收益率:-11.75%
市净率:4.04
市盈率(LYR):-8.51

数据加载中...

公司资料

公司名字:
Soleno Therapeutics
交易所:
NASDAQ
成立时间:
1999
员工人数:
152
公司地址:
100 Marine Parkway,Suite 400,Redwood City,California,United States
邮编:
94065
电话:
传真:
650 213 8383
简介:
Soleno Therapeutics, Inc.于1999年8月25日在特拉华州成立。该公司专注于治疗罕见病的新型疗法的开发和商业化。该公司的主要候选药物DCCR(二氮嗪胆碱)缓释片是一种有效的ATP敏感钾(KATP)通道激活剂。

董事

名称
职位
Anish Bhatnagar
CEO and Chairman of the Board
Matthew Pauls
Lead Independent Director
Andrew Sinclair
Director
Birgitte Volck
Director
Dawn Bir
Director
Mark W. Hahn
Director
William G. Harris
Director

股东

名称
职位
James Mackaness
Chief Financial Officer
Kristen Yen
Senior Vice President of Global Clinical Operations and Patient Advocacy
Michael Huang
Senior Vice President of Clinical Development
Patricia Hirano
Senior Vice President of Regulatory Affairs
Anish Bhatnagar
CEO and Chairman of the Board
Meredith Manning
Chief Commercial Officer